Davey, R.T. Jr. et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl Acad. Sci. USA 96, 15109−15114

National Institute of Allergy and Infectious Diseases, (NIAID), National Institutes of Health, Bethesda, MD 20892, USA.
Proceedings of the National Academy of Sciences (Impact Factor: 9.67). 12/1999; 96(26):15109-15114. DOI: 10.1073/pnas.96.26.15109
Source: PubMed


Identifying the immunologic and virologic consequences of discontinuing antiretroviral therapy in HIV-infected patients is
of major importance in developing long-term treatment strategies for patients with HIV-1 infection. We designed a trial to
characterize these parameters after interruption of highly active antiretroviral therapy (HAART) in patients who had maintained
prolonged viral suppression on antiretroviral drugs. Eighteen patients with CD4+ T cell counts ≥ 350 cells/μl and viral load below the limits of detection for ≥1 year while on HAART were enrolled prospectively
in a trial in which HAART was discontinued. Twelve of these patients had received prior IL-2 therapy and had low frequencies
of resting, latently infected CD4 cells. Viral load relapse to >50 copies/ml occurred in all 18 patients independent of prior
IL-2 treatment, beginning most commonly during weeks 2–3 after cessation of HAART. The mean relapse rate constant was 0.45
(0.20 log10 copies) day−1, which was very similar to the mean viral clearance rate constant after drug resumption of 0.35 (0.15 log10 copies) day−1 (P = 0.28). One patient experienced a relapse delay to week 7. All patients except one experienced a relapse burden to >5,000
RNA copies/ml. Ex vivo labeling with BrdUrd showed that CD4 and CD8 cell turnover increased after withdrawal of HAART and correlated with viral
load whereas lymphocyte turnover decreased after reinitiation of drug treatment. Virologic relapse occurs rapidly in patients
who discontinue suppressive drug therapy, even in patients with a markedly diminished pool of resting, latently infected CD4+ T cells.

Download full-text


Available from: Richard A Lempicki
  • Source
    • "Data from NK cell function and receptor expression may be used in this context to help understand existing differences. When antiretroviral treatment is interrupted in chronically infected patients, viral replication invariably resumes even after thorough and extensive treatment (90). Trials of CD4+-guided treatment interruptions (CD4GTI) in patients with high CD4+ T cell showed that the rate of CD4+-cell loss after discontinuation of antiretroviral treatment is dishomogeneous with ample divergence and inter-individual differences (91, 92). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Natural killer (NK) cell function is regulated by a balance between the triggering of activating and inhibitory receptors expressed on their surface. A relevant effort has been focused so far on the study of KIR carriage/expression setting the basis for NK cell education and self-tolerance. Focus on the evolution and regulation of activating NK receptors has lagged behind so far. Our understanding of activating receptor expression and regulation has recently improved by evidences derived from in vitro and in vivo studies. Virus infection - either acute or chronic - determines preferential expansion of NK cells with specific phenotype, activating receptors, and with recall-like functional activity. Studies on patients with viral infection (HIV and HCV) and specific diverging clinical courses confirm that inter-individual differences may exist in baseline expression of natural cytotoxicity receptors (NKp46 and NKp30). The findings that patients with divergent clinical courses have different kinetics of activating receptor density expression upon NK cell activation in vitro provide an additional, time-dependent, functional parameter. Kinetic changes in receptor expression thus represent an additional parameter to basal receptor density expression. Different expression and inducibilities of activating receptors on NK cells contribute to the high diversity of NK cell populations and may help our understanding of the inter-individual differences in innate responses that underlie divergent disease courses.
    Full-text · Article · Jul 2014 · Frontiers in Immunology
  • Source
    • "However, this regimen is associated with several comorbidities, requires strict compliance with a lifelong drug regimen, and has little impact on the elimination of the HIV-1 reservoir [1•]. Latently infected, resting CD4+ T cells have been shown to persist in HIV-1 infected individuals treated with ART who otherwise have minimal levels of virus in the plasma [2, 3••]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite the success of antiretroviral therapy in suppressing HIV-1 replication and extending the life of HIV-1 infected individuals, this regimen is associated with risks for non-AIDS morbidity and mortality, requires life commitment, and has a high cost. In this context, gene therapy approaches that have the potential to cure HIV-1 infection present a clear option for eradication of the virus in the next decades. Gene therapy must overcome concerns related to its applicability to HIV-1 infection, the safety of cytotoxic conditioning required for cell-based approaches, clinical trial design, selection of gene-modified cells, and the restrictive cost of manufacturing and technology. These concerns are discussed herein in the context of the most relevant gene therapy studies conducted so far in HIV/AIDS.
    Full-text · Article · Jan 2014 · Current HIV/AIDS Reports
  • Source
    • "Highly active antiretroviral therapy (HAART) can suppress HIV-1 replication in infected patients, but the ability of HIV to persist as an inducible reservoir of latent proviruses [1-3] obstructs eradication of the virus and functional cure [4]. These latent proviruses are long lived [5,6] and relatively invisible to the immune system [2,7]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: HIV infection can be treated effectively with antiretroviral agents, but the persistence of a latent reservoir of integrated proviruses prevents eradication of HIV from infected individuals. The chromosomal environment of integrated proviruses has been proposed to influence HIV latency, but the determinants of transcriptional repression have not been fully clarified, and it is unclear whether the same molecular mechanisms drive latency in different cell culture models. Here we compare data from five different in vitro models of latency based on primary human T cells or a T cell line. Cells were infected in vitro and separated into fractions containing proviruses that were either expressed or silent/inducible, and integration site populations sequenced from each. We compared the locations of 6,252 expressed proviruses to those of 6,184 silent/inducible proviruses with respect to 140 forms of genomic annotation, many analyzed over chromosomal intervals of multiple lengths. A regularized logistic regression model linking proviral expression status to genomic features revealed no predictors of latency that performed better than chance, though several genomic features were significantly associated with proviral expression in individual models. Proviruses in the same chromosomal region did tend to share the same expressed or silent/inducible status if they were from the same cell culture model, but not if they were from different models. The silent/inducible phenotype appears to be associated with chromosomal position, but the molecular basis is not fully clarified and may differ among in vitro models of latency.
    Full-text · Article · Aug 2013 · Retrovirology
Show more